ORIGIN Results in Detail: Numbers, Subgroups, and Time Course

At a glance

| Field | Detail | |---|---| | Trial | ORIGIN (Outcome Reduction with Initial Glargine Intervention) | | N | 12,537 | | Population | Age ≥50, CV risk factors, plus IFG, IGT, or early T2D | | Intervention | Insulin glargine (Lantus), titrated to fasting plasma glucose <95 mg/dL | | Comparator | Standard care (lifestyle ± oral agents at investigator discretion) | | Median follow-up | 6.2 years | | Primary endpoint | Composite of CV death, nonfatal MI, or nonfatal stroke | | Co-primary endpoint | Above composite plus revascularization or hospitalization for heart failure | | Key result | Neutral on both co-primary endpoints; 28% reduction in new T2D onset |

Why the Numbers Matter More Than the Headline

The ORIGIN trial was designed to answer a question that had lingered for decades: does early basal insulin in people who are not yet overtly diabetic (or only recently diagnosed) prevent cardiovascular events, or does it cause them? Prior observational data had cut both ways. Some registries linked exogenous insulin to higher CV mortality; mechanistic arguments about insulin's mitogenic and anti-atherogenic properties pointed in opposite directions. ORIGIN was powered to detect a 15% relative risk reduction, which meant the trial also had the statistical muscle to rule out meaningful harm.

Primary Endpoint: The Core Numbers

The first co-primary composite (CV death, nonfatal MI, nonfatal stroke) occurred in 2.94 per 100 person-years in the glargine arm and 2.85 per 100 person-years in the standard-care arm.

| Outcome | Glargine (n = 6,264) | Standard Care (n = 6,273) | HR (95% CI) | p-value | |---|---|---|---|---| | Co-primary composite #1 | 970 (15.5%) | 953 (15.2%) | 1.02 (0.94-1.11) | 0.63 | | Co-primary composite #2 | 1,237 (19.7%) | 1,252 (20.0%) | 0.99 (0.91-1.07) | 0.74 | | CV death | 580 (9.3%) | 576 (9.2%) | 1.00 (0.89-1.13) | 0.98 | | Nonfatal MI | 336 (5.4%) | 326 (5.2%) | 1.04 (0.89-1.21) | 0.65 | | Nonfatal stroke | 166 (2.7%) | 164 (2.6%) | 1.01 (0.82-1.26) | 0.89 | | All-cause mortality | 951 (15.2%) | 965 (15.4%) | 0.98 (0.90-1.08) | 0.70 |

Every point estimate sits near 1.00, and every confidence interval excludes both a 15% benefit and a 15% harm. The published results confirmed that the trial met its non-inferiority threshold for CV safety while failing to show superiority. This pattern held across sensitivity analyses that censored participants who crossed over to open-label insulin.

Secondary Endpoints and Pre-specified Analyses

Beyond the composite, ORIGIN tracked microvascular outcomes and metabolic endpoints.

New-onset type 2 diabetes. Among participants without diabetes at baseline (n = 1,456), glargine reduced progression to overt T2D by 28% (HR 0.72, 95% CI 0.58-0.91, p = 0.006) at the end of the in-trial period. Three months after washout, the difference narrowed but still favored glargine (odds ratio 0.75, 95% CI 0.59-0.96). This suggested partial disease modification rather than mere glucose suppression.

Cancer incidence. A pre-specified safety analysis found no increase in any cancer or organ-specific cancer with glargine. Total cancers occurred in 5.7% of glargine patients vs. 5.8% of standard-care patients (HR 0.99, 95% CI 0.85-1.16). This result was important given prior controversies about insulin glargine and cancer risk raised by observational database studies.

Hypoglycemia. Severe hypoglycemia (requiring assistance) was significantly more common with glargine: 1.00 vs. 0.31 per 100 person-years. Over the full trial, 5.7% of glargine patients experienced at least one severe episode vs. 1.8% in the standard-care arm. Non-severe confirmed symptomatic hypoglycemia (<54 mg/dL) occurred at 16.7 vs. 5.2 events per 100 person-years.

Body weight. Glargine produced a mean weight gain of approximately 1.6 kg more than standard care over the follow-up period. Weight trajectories diverged early and plateaued after year 2, which aligns with the titration-to-target design reaching steady state.

Time-Course Patterns

Kaplan-Meier curves for both co-primary endpoints tracked almost perfectly superimposed from randomization through year 7. There was no early divergence (no early harm signal) and no late divergence (no late benefit signal). The ORIGIN investigators noted that the curves remained parallel, which argues against a delayed cardioprotective effect that might have emerged with longer follow-up.

HbA1c separation between arms was modest. Glargine reduced median HbA1c to approximately 6.2% vs. 6.5% in standard care by 2 years. That 0.3 percentage-point gap persisted through follow-up. Fasting glucose showed a larger and more immediate split: median values of approximately 95 mg/dL (the titration target) vs. 118 mg/dL in standard care by year 1.

The glucose separation confirms adequate pharmacologic contrast, but the relatively small HbA1c gap may partly explain the neutral CV outcome. Basal insulin addresses fasting glucose far more than postprandial excursions, and the net glycemic exposure difference may have been too small to move atherosclerotic endpoints over this time horizon.

Subgroup Analyses

ORIGIN reported pre-specified subgroup analyses across 14 baseline characteristics. None showed statistically significant interaction terms (all p-interaction > 0.05), reinforcing the consistency of the neutral finding.

| Subgroup | Glargine HR (95% CI) | p-interaction | |---|---|---| | Prior CVD (yes vs. no) | 1.01 / 1.06 | 0.68 | | Baseline HbA1c (<6.4% vs. ≥6.4%) | 1.05 / 0.99 | 0.53 | | Diabetes at baseline (yes vs. no) | 1.01 / 1.08 | 0.56 | | Region (North America/Europe vs. other) | 1.01 / 1.04 | 0.80 | | Age (<64 vs. ≥64 years) | 1.07 / 0.98 | 0.37 | | BMI (<30 vs. ≥30 kg/m²) | 1.05 / 0.99 | 0.50 | | Sex (male vs. female) | 0.99 / 1.10 | 0.33 |

The absence of any subgroup signal means there is no hidden population for whom glargine was clearly beneficial or harmful in CV terms. This is an unusually clean null result.

Response Distribution: Glucose Control Achieved

Rather than reporting only means, the ORIGIN dataset allows examination of glucose control distribution. At year 2, approximately 50% of glargine patients achieved fasting glucose <95 mg/dL (the protocol target). The median glargine dose was 0.31 U/kg/day (IQR approximately 0.20-0.46), reflecting the conservative titration approach. Roughly 25% of participants required insulin doses above 40 units daily.

In the standard-care arm, 42% of participants were receiving metformin and 21% were on sulfonylureas by the end of follow-up. Approximately 11% of standard-care patients crossed over to insulin during the trial, which dilutes the between-group contrast but reflects real-world clinical decision-making.

What the Authors Acknowledged as Limitations

The ORIGIN investigators were transparent about several constraints. The trial enrolled a population at high cardiovascular risk (prior CVD in ~59%) but with relatively well-controlled glucose at baseline (median HbA1c 6.4%). The small glycemic separation between arms may have limited the trial's ability to detect a glucose-mediated CV benefit. The population also received aggressive background CV therapy: over 50% were on statins, and a similar proportion used ACE inhibitors or ARBs per contemporary guidelines endorsed by the ADA Standards of Care.

The 2x2 factorial design (glargine vs. standard care AND omega-3 fatty acids vs. placebo) was pre-tested for interaction and found none, but factorial trials always carry the theoretical risk of masking effects.

Selection bias in enrollment is also worth noting. Patients willing to inject daily insulin and self-monitor were a motivated subset, possibly healthier than the broader early-dysglycemia population.

Clinical Translation

The ORIGIN results had immediate practice implications. First, they retired the hypothesis that exogenous insulin itself causes cardiovascular harm. This was consistent with the later DEVOTE trial showing CV safety of insulin degludec and with the FDA's 2008 guidance requiring CV outcome trials for diabetes drugs. Second, they showed that treating pre-diabetes with basal insulin does not prevent heart attacks or strokes, which redirected clinical attention toward agents that eventually did show CV benefit (GLP-1 receptor agonists, SGLT2 inhibitors).

The 28% reduction in new-onset diabetes is noteworthy but has not changed guidelines. No major society recommends insulin for diabetes prevention because the benefit requires indefinite injections, carries hypoglycemia risk, and attenuates after discontinuation.

How ORIGIN Compares to Subsequent Insulin CV Trials

| Trial | Year | Insulin | N | Median F/U | CV composite HR (95% CI) | |---|---|---|---|---|---| | ORIGIN | 2012 | Glargine | 12,537 | 6.2 yr | 1.02 (0.94-1.11) | | DEVOTE | 2017 | Degludec vs. glargine | 7,637 | 1.99 yr | 0.91 (0.78-1.06) |

Both trials confirmed neutral CV outcomes with basal insulin. DEVOTE's shorter duration and active-comparator design limits direct comparison, but the consistency of findings across insulins strengthens the class-level safety conclusion per current ADA guidelines.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. PubMed
2. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes (DEVOTE). N Engl J Med. 2017;377(8):723-732. PubMed
3. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Diabetologia. 2009;52(9):1732-1744. PubMed
4. FDA Guidance for Industry: Diabetes Mellitus, Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes (2008). FDA.gov
5. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2023. Diabetes Care. 2023;46(Suppl 1). PubMed